Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) has earned an average rating of “Hold” from the eleven brokerages that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $28.60.
MYGN has been the subject of a number of recent research reports. Wells Fargo & Company initiated coverage on Myriad Genetics in a research note on Tuesday, August 27th. They set an “overweight” rating and a $35.00 price target for the company. Jefferies Financial Group restated an “underperform” rating and set a $20.00 price target (down from $25.00) on shares of Myriad Genetics in a research note on Monday, June 3rd. JPMorgan Chase & Co. boosted their price target on Myriad Genetics from $17.00 to $20.00 and gave the company an “underweight” rating in a research note on Wednesday, August 7th. TD Cowen boosted their price target on Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Finally, Scotiabank boosted their price target on Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a research note on Tuesday, August 13th.
Get Our Latest Research Report on MYGN
Insider Activity
Institutional Trading of Myriad Genetics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sanctuary Advisors LLC purchased a new stake in Myriad Genetics in the second quarter worth $537,000. Maven Securities LTD purchased a new stake in Myriad Genetics in the second quarter worth $1,223,000. Point72 Asset Management L.P. increased its stake in Myriad Genetics by 7.9% in the second quarter. Point72 Asset Management L.P. now owns 839,456 shares of the company’s stock worth $20,533,000 after purchasing an additional 61,260 shares during the period. Disciplined Growth Investors Inc. MN increased its stake in Myriad Genetics by 0.5% in the second quarter. Disciplined Growth Investors Inc. MN now owns 2,087,328 shares of the company’s stock worth $51,056,000 after purchasing an additional 10,035 shares during the period. Finally, Algert Global LLC purchased a new stake in Myriad Genetics in the second quarter worth $221,000. Hedge funds and other institutional investors own 99.02% of the company’s stock.
Myriad Genetics Price Performance
MYGN opened at $27.59 on Friday. The company’s 50-day simple moving average is $27.23 and its two-hundred day simple moving average is $23.92. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.78 and a current ratio of 1.96. The stock has a market capitalization of $2.51 billion, a P/E ratio of -9.78 and a beta of 1.92. Myriad Genetics has a 52-week low of $13.82 and a 52-week high of $29.08.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.06. The company had revenue of $211.50 million for the quarter, compared to analysts’ expectations of $206.44 million. Myriad Genetics had a negative net margin of 19.35% and a negative return on equity of 5.64%. The firm’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.21) earnings per share. As a group, analysts predict that Myriad Genetics will post -0.34 EPS for the current year.
About Myriad Genetics
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Featured Stories
- Five stocks we like better than Myriad Genetics
- 10 Best Airline Stocks to Buy
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- How to Buy Cheap Stocks Step by Step
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- How Technical Indicators Can Help You Find Oversold StocksÂ
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.